Browse News
Filter News
Found 644,324 articles
-
MIVI Neuroscience Secures Series B Funding - Jan 21, 2021
1/21/2021
MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, announced the closing of its Series B funding including $35 million in new money plus the conversion of previously issued convertible notes.
-
CareDx Announces Pricing of Public Offering of Common Stock - Jan 21, 2021
1/21/2021
CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the pricing of an underwritten public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share.
-
INOVIO Announces Pricing of Public Offering of Common Stock - Jan 21, 2021
1/21/2021
INOVIO Pharmaceuticals, Inc., a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share.
-
CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - Jan 21, 2021
1/21/2021
CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by CytomX.
-
Editas Medicine Announces Pricing of Offering of Common Stock - Jan 21, 2021
1/21/2021
Editas Medicine, Inc., a leading gene editing company, announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.
-
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
1/21/2021
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $28.00 per share
-
Taro to Announce Third Quarter Results on January 27, 2021
1/21/2021
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2020, after the close of market on Wednesday, January 27, 2021.
-
Chimerix Announces Pricing of Public Offering of Common Stock
1/21/2021
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of $8.50 per share
-
Athira Pharma Announces Pricing of Public Offering of Common Stock
1/21/2021
Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share.
-
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
1/21/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced that it has signed a binding agreement with the Company's main shareholder GEM Global Yield LLC SCS for the implementation of a new Share Subscription Facility in the amount of up to CHF 50 million.
-
Sapreme Appoints Henrik Luessen as Chief Business Officer
1/21/2021
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced the appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer.
-
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States
1/21/2021
ViaDerma, Inc., announces the completion of a licensing agreement with a group of affiliated wound care medical practices.
-
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
1/21/2021
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
-
Polpharma Biologics Announces Rebrand and Launch of New Value “We Care” as 2000 L Bioreactors Begin Validation at Its Warsaw Site
1/21/2021
European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative.
-
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial
1/21/2021
Calliditas Therapeutics AB announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.
-
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
1/21/2021
LumiraDx, the next-generation point-of-care diagnostic testing company, announced multinational approvals of its SARS-CoV-2 Antigen Test.
-
Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors
1/21/2021
Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the appointment of Jean M. Franchi to its Board of Directors.
-
First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
1/21/2021
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050.
-
FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
1/21/2021
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priority Review for Esbriet® for the treatment of unclassifiable interstitial lung disease.
-
The U.S. Food and Drug Administration approved Merck and Bayer’s heart failure drug vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, the pharma giants announced this morning.